Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Apr 14, 2009

Premium

Jonathan "Jack" Lord has been appointed as president and CEO of Navigenics and will assume his new position May 1. He replaces Mari Baker, who left the company in March. Lord joins Navigenics from Humana, where he was senior vice president and chief innovation officer. Prior to that, he was president of Health Dialog.


Lisa Wise has been named chief operating officer, and James O'Leary has been appointed chief innovation officer, a new position, of Genetic Alliance, a non-profit health advocacy organization.

Wiese has been with Genetic Alliance for more than five years, focusing on a variety of projects. Her new responsibilities will include integrating operations with new strategic demands of the organization. She holds bachelor's degrees in political science and media arts and a master's degree in communications from the University of Arizona.

O'Leary will direct strategic innovation as Genetic Alliance broadens its service to the genetics community.


Paul Keim has been appointed to the scientific advisory board of Febit. He is a senior investigator and director of the pathogen genomics division at the Translational Genomics Research Institute in Phoenix, Ariz., and a professor of biology at Northern Arizona University. Febit said Keim's expertise will be "particularly helpful in Febit's research activities in the field of biosecurity," and he will be a partner in developing new applications for the company's HybSelect sequence capture method.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.